Organized around addressing radiation induced injury suffered by patients after they have undergone radiation therapy, Fibroplate, Inc. (FB) is an early stage biopharmaceutical company working on the first-in-class fibrinogen-coated albumin nanosphere (FAS). The technology has been shown to offer the potential to improve the conditions of many patients with serous medical conditions. Of particular focus are cancer patients who have received radiation therapy and who suffer from the effects of high dose irradiation. The product is a ready-to-use suspension of biocompatible protein nanospheres which works immediately after intravenous administration to patients, resulting in the mitigation and therapeutic treatment of radiation harm
